{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:20:19Z","timestamp":1788337219610,"version":"build-2803163510"},"reference-count":99,"publisher":"BMJ","issue":"Suppl 9","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2023,11,1]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>\n                    <jats:italic>Streptococcus pyogenes,<\/jats:italic>\n                    also known as group A streptococcus (StrepA), is a bacterium that causes a range of human diseases, including pharyngitis, impetigo, invasive infections, and post-infection immune sequelae such as rheumatic fever and rheumatic heart disease. StrepA infections cause some of the highest burden of disease and death in mostly young populations in low-resource settings. Despite decades of effort, there is still no licensed StrepA vaccine, which if developed, could be a cost-effective way to reduce the incidence of disease. Several challenges, including technical and regulatory hurdles, safety concerns and a lack of investment have hindered StrepA vaccine development. Barriers to developing a StrepA vaccine must be overcome in the future by prioritising key areas of research including greater understanding of StrepA immunobiology and autoimmunity risk, better animal models that mimic human disease, expanding the StrepA vaccine pipeline and supporting vaccine clinical trials. The development of a StrepA vaccine is a complex and challenging process that requires significant resources and investment. Given the global burden of StrepA infections and the potential for a vaccine to save lives and livelihoods, StrepA vaccine development is an area of research that deserves considerable support. This report summarises the findings of the Primordial Prevention Working Group-VAX, which was convened in November 2021 by the National Heart, Lung, and Blood Institute. The focus of this report is to identify research gaps within the current StrepA vaccine landscape and find opportunities and develop priorities to promote the rapid and successful advancement of StrepA vaccines.\n                  <\/jats:p>","DOI":"10.1136\/bmjgh-2023-013534","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T23:20:14Z","timestamp":1702423214000},"page":"e013534","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Research opportunities for the primordial prevention of rheumatic fever and rheumatic heart disease\u2014streptococcal vaccine development: a national heart, lung and blood institute workshop report"],"prefix":"10.1136","volume":"8","author":[{"given":"Alma","family":"Fulurija","sequence":"first","affiliation":[{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Western Australia, Australia"},{"name":"Centre for Child Health Research, The University of Western Australia, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine W","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Korotkova","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3369-9183","authenticated-orcid":false,"given":"Mary Y.","family":"Masterson","sequence":"additional","affiliation":[{"name":"Center for Translation Research and Implementation Science (CTRIS), National Heart Lung and Blood Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha P.","family":"Bansal","sequence":"additional","affiliation":[{"name":"John E Fogarty International Center, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Otago Wellington, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Cannon","sequence":"additional","affiliation":[{"name":"Centre for Child Health Research, The University of Western Australia, Perth, Western Australia, Australia"},{"name":"Department of Global Health and Population, Harvard University T H Chan School of Public Health, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Carapetis","sequence":"additional","affiliation":[{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Western Australia, Australia"},{"name":"Centre for Child Health Research, The University of Western Australia, Perth, Western Australia, Australia"},{"name":"Department of Infectious Diseases, Perth Children's Hospital, Nedlands, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Steer","sequence":"additional","affiliation":[{"name":"Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"2025073014552562000_8.Suppl_9.e013534.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70267-X"},{"key":"2025073014552562000_8.Suppl_9.e013534.2","doi-asserted-by":"publisher","DOI":"10.1007\/82_2012_280"},{"key":"2025073014552562000_8.Suppl_9.e013534.3","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00101-13"},{"key":"2025073014552562000_8.Suppl_9.e013534.4","doi-asserted-by":"crossref","first-page":"101458","DOI":"10.1016\/j.eclinm.2022.101458","article-title":"The global burden of sore throat and group A streptococcus pharyngitis: a systematic review and meta-analysis","volume":"48","author":"Miller","year":"2022","journal-title":"eClinicalMedicine"},{"key":"2025073014552562000_8.Suppl_9.e013534.5","unstructured":"Craik N , Hla T , Cannon J , et al . Global disease burden of Streptococcus Pyogenes. In: Ferretti JJ , Stevens DL , Fischetti VA , eds. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. 2nd edn. Oklahoma City (OK), 2022."},{"key":"2025073014552562000_8.Suppl_9.e013534.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603693"},{"key":"2025073014552562000_8.Suppl_9.e013534.7","doi-asserted-by":"crossref","unstructured":"Cho KH , Port GC , Caparon M . Genetics of group A streptococci. Microbiol Spectr 2019;7. doi:10.1128\/microbiolspec.GPP3-0056-2018","DOI":"10.1128\/microbiolspec.GPP3-0056-2018"},{"key":"2025073014552562000_8.Suppl_9.e013534.8","doi-asserted-by":"crossref","DOI":"10.1038\/s41579-023-00939-6","article-title":"Author correction: pathogenesis, epidemiology and control of group A streptococcus infection","volume":"21","author":"Brouwer","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2025073014552562000_8.Suppl_9.e013534.9","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1111\/jam.15090","article-title":"A current review of pathogenicity determinants of streptococcus SP","volume":"131","author":"Lannes-Costa","year":"2021","journal-title":"J Appl Microbiol"},{"key":"2025073014552562000_8.Suppl_9.e013534.10","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000644"},{"key":"2025073014552562000_8.Suppl_9.e013534.11","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2019.00137","article-title":"Modeling streptococcus pyogenes pharyngeal colonization in the mouse","volume":"9","author":"Gogos","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"2025073014552562000_8.Suppl_9.e013534.12","unstructured":"Watson ME , Neely MN , Caparon MG . Animal models of Streptococcus Pyogenes infection. In: Ferretti JJ , Stevens DL , Fischetti VA , eds. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. Oklahoma City (OK), 2016."},{"key":"2025073014552562000_8.Suppl_9.e013534.13","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03537-20","article-title":"Prime-pull immunization with a bivalent M-protein and spy-CEP peptide vaccine adjuvanted with CAF(R)01 liposomes induces both mucosal and peripheral protection from covR\/S mutant streptococcus pyogenes","volume":"12","author":"Ozberk","year":"2021","journal-title":"mBio"},{"key":"2025073014552562000_8.Suppl_9.e013534.14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-80508-6","article-title":"Preclinical safety and immunogenicity of streptococcus pyogenes (Strep A) peptide vaccines","volume":"11","author":"Reynolds","year":"2021","journal-title":"Sci Rep"},{"key":"2025073014552562000_8.Suppl_9.e013534.15","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.4049\/jimmunol.145.4.1251","article-title":"Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. protection against a heterologous M serotype with shared C repeat region epitopes","volume":"145","author":"Bessen","year":"1990","journal-title":"J Immunol"},{"key":"2025073014552562000_8.Suppl_9.e013534.16","doi-asserted-by":"publisher","DOI":"10.1086\/374800"},{"key":"2025073014552562000_8.Suppl_9.e013534.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060969","article-title":"Streptincor: a candidate vaccine EPITOPE against S. Pyogenes infections induces protection in outbred mice","volume":"8","author":"Postol","year":"2013","journal-title":"PLoS One"},{"key":"2025073014552562000_8.Suppl_9.e013534.18","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00122-20","article-title":"Vaccine-induced Th1-type response protects against invasive group A streptococcus infection in the absence of opsonizing antibodies","volume":"11","author":"Rivera-Hernandez","year":"2020","journal-title":"mBio"},{"key":"2025073014552562000_8.Suppl_9.e013534.19","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00693-19","article-title":"An experimental group A streptococcus vaccine that reduces pharyngitis and tonsillitis in a nonhuman primate model","volume":"10","author":"Rivera-Hernandez","year":"2019","journal-title":"mBio"},{"key":"2025073014552562000_8.Suppl_9.e013534.20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-1-0716-0467-0_24","article-title":"Humanized plasminogen mouse model to study group A streptococcus invasive disease","volume":"2136","author":"Rivera-Hernandez","year":"2020","journal-title":"Methods Mol Biol"},{"key":"2025073014552562000_8.Suppl_9.e013534.21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.molimm.2021.04.010","article-title":"Non-human primate models of human respiratory infections","volume":"135","author":"Lemaitre","year":"2021","journal-title":"Mol Immunol"},{"key":"2025073014552562000_8.Suppl_9.e013534.22","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2014.00116","article-title":"Animal models to investigate the pathogenesis of rheumatic heart disease","volume":"2","author":"Rush","year":"2014","journal-title":"Front Pediatr"},{"key":"2025073014552562000_8.Suppl_9.e013534.23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/08916934.2019.1605356","article-title":"Group A streptococcal M-protein specific antibodies and T-cells drive the pathology observed in the rat autoimmune Valvulitis model","volume":"52","author":"Sikder","year":"2019","journal-title":"Autoimmunity"},{"key":"2025073014552562000_8.Suppl_9.e013534.24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/imcb.12571","article-title":"Characterization of an experimental model to determine streptococcal M protein-induced autoimmune cardiac and neurobehavioral abnormalities","volume":"100","author":"Rafeek","year":"2022","journal-title":"Immunol Cell Biol"},{"key":"2025073014552562000_8.Suppl_9.e013534.25","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.6.4072-4078.2001"},{"key":"2025073014552562000_8.Suppl_9.e013534.26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/08916934.2016.1217999","article-title":"Repeat exposure to group A streptococcal M protein exacerbates cardiac damage in a rat model of rheumatic heart disease","volume":"49","author":"Gorton","year":"2016","journal-title":"Autoimmunity"},{"key":"2025073014552562000_8.Suppl_9.e013534.27","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.56"},{"key":"2025073014552562000_8.Suppl_9.e013534.28","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/S2666-5247(20)30240-8","article-title":"A controlled human infection model of streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study","volume":"2","author":"Osowicki","year":"2021","journal-title":"Lancet Microbe"},{"key":"2025073014552562000_8.Suppl_9.e013534.29","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00647-18","article-title":"A controlled human infection model of group A streptococcus pharyngitis: which strain and why? mSphere","volume":"4","author":"Osowicki","year":"2019","journal-title":"mSphere"},{"key":"2025073014552562000_8.Suppl_9.e013534.30","doi-asserted-by":"crossref","first-page":"101429","DOI":"10.1016\/j.smim.2020.101429","article-title":"Human challenge trials in vaccine development","volume":"50","author":"Sekhar","year":"2020","journal-title":"Semin Immunol"},{"key":"2025073014552562000_8.Suppl_9.e013534.31","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1580577"},{"key":"2025073014552562000_8.Suppl_9.e013534.32","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70178-1"},{"key":"2025073014552562000_8.Suppl_9.e013534.33","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00609-x","article-title":"The streptococcus pyogenes vaccine landscape","volume":"8","author":"Walkinshaw","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2025073014552562000_8.Suppl_9.e013534.34","unstructured":"Harbison-Price N , Rivera-Hernandez T , Osowicki J , et al . Current approaches to vaccine development of Streptococcus Pyogenes. In: Ferretti JJ , Stevens DL , Fischetti VA , eds. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. 2nd edn. Oklahoma City (OK), 2022."},{"key":"2025073014552562000_8.Suppl_9.e013534.35","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/138.6.712"},{"key":"2025073014552562000_8.Suppl_9.e013534.36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107372"},{"key":"2025073014552562000_8.Suppl_9.e013534.37","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/131.3.217"},{"key":"2025073014552562000_8.Suppl_9.e013534.38","first-page":"429","article-title":"Group A streptococcal M protein vaccine: protection following immunization via the respiratory tract","volume":"28","author":"Waldman","year":"1975","journal-title":"Dev Biol Stand"},{"key":"2025073014552562000_8.Suppl_9.e013534.39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1969.03150190037007"},{"key":"2025073014552562000_8.Suppl_9.e013534.40","doi-asserted-by":"crossref","first-page":"15084","DOI":"10.1038\/nrdp.2015.84","article-title":"Acute rheumatic fever and rheumatic heart disease","volume":"2","author":"Carapetis","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2025073014552562000_8.Suppl_9.e013534.41","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.3.470"},{"key":"2025073014552562000_8.Suppl_9.e013534.42","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy11435280612"},{"key":"2025073014552562000_8.Suppl_9.e013534.43","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.919700","article-title":"Igg2 rules: N-acetyl-beta-D-Glucosamine-specific Igg2 and Th17\/Th1 cooperation may promote the pathogenesis of acute rheumatic heart disease and be a biomarker of the autoimmune sequelae of streptococcus pyogenes","volume":"9","author":"Kirvan","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2025073014552562000_8.Suppl_9.e013534.44","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.6.709"},{"key":"2025073014552562000_8.Suppl_9.e013534.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.12.005"},{"key":"2025073014552562000_8.Suppl_9.e013534.46","doi-asserted-by":"publisher","DOI":"10.1086\/498618"},{"key":"2025073014552562000_8.Suppl_9.e013534.47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1128\/iai.8.1.19-24.1973","article-title":"Type specific inhibition of preopsonization versus immunoprecipitation by streptococcal M proteins","volume":"8","author":"Beachey","year":"1973","journal-title":"Infect Immun"},{"key":"2025073014552562000_8.Suppl_9.e013534.48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198658","article-title":"Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (Mj8Vax) in a randomized clinical trial","volume":"13","author":"Sekuloski","year":"2018","journal-title":"PLoS One"},{"key":"2025073014552562000_8.Suppl_9.e013534.49","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M111.015693","article-title":"Multi high-throughput approach for highly selective identification of vaccine candidates: the group A streptococcus case","volume":"11","author":"Bensi","year":"2012","journal-title":"Mol Cell Proteomics"},{"key":"2025073014552562000_8.Suppl_9.e013534.50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228558","article-title":"Rational design of a glycoconjugate vaccine against group A streptococcus","volume":"21","author":"Di Benedetto","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025073014552562000_8.Suppl_9.e013534.51","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00292-21","article-title":"Immunobiology of the classical lancefield group A streptococcal carbohydrate antigen","volume":"89","author":"Gao","year":"2021","journal-title":"Infect Immun"},{"key":"2025073014552562000_8.Suppl_9.e013534.52","doi-asserted-by":"crossref","DOI":"10.1038\/s41588-019-0482-z","article-title":"Author correction: atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics","volume":"51","author":"Davies","year":"2019","journal-title":"Nat Genet"},{"key":"2025073014552562000_8.Suppl_9.e013534.53","doi-asserted-by":"publisher","DOI":"10.1007\/82_2012_284"},{"key":"2025073014552562000_8.Suppl_9.e013534.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.04.030"},{"key":"2025073014552562000_8.Suppl_9.e013534.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.09.018"},{"key":"2025073014552562000_8.Suppl_9.e013534.56","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00618-16","article-title":"Differing efficacies of lead group A streptococcal vaccine candidates and full-length M protein in cutaneous and invasive disease models","volume":"7","author":"Rivera-Hernandez","year":"2016","journal-title":"mBio"},{"key":"2025073014552562000_8.Suppl_9.e013534.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.08.113"},{"key":"2025073014552562000_8.Suppl_9.e013534.58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-83673-4","article-title":"A multivalent T-antigen-based vaccine for group A streptococcus","volume":"11","author":"Loh","year":"2021","journal-title":"Sci Rep"},{"key":"2025073014552562000_8.Suppl_9.e013534.59","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1016\/j.vaccine.2014.04.092","article-title":"Development of a recombinant fusion protein vaccine formulation to protect against streptococcus pyogenes","volume":"32","author":"Morefield","year":"2014","journal-title":"Vaccine"},{"key":"2025073014552562000_8.Suppl_9.e013534.60","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/jat.3349","article-title":"Preclinical safety study of a recombinant streptococcus pyogenes vaccine formulated with aluminum adjuvant","volume":"37","author":"HogenEsch","year":"2017","journal-title":"J Appl Toxicol"},{"key":"2025073014552562000_8.Suppl_9.e013534.61","doi-asserted-by":"publisher","DOI":"10.1172\/JCI7132"},{"key":"2025073014552562000_8.Suppl_9.e013534.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2014.05.009"},{"key":"2025073014552562000_8.Suppl_9.e013534.63","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/IM9.0000000000000044","article-title":"Site-specific conjugation of cell wall polyrhamnose to protein spyad envisioning a safe universal group A streptococcal vaccine","volume":"3","author":"Gao","year":"2020","journal-title":"Infectious Microbes and Diseases"},{"key":"2025073014552562000_8.Suppl_9.e013534.64","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00639-5","article-title":"Progress towards a glycoconjugate vaccine against group A streptococcus","volume":"8","author":"Burns","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2025073014552562000_8.Suppl_9.e013534.65","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-07602-0","article-title":"Mucosal vaccination with Pili from group A streptococcus expressed on lactococcus lactis generates protective immune responses","volume":"7","author":"Loh","year":"2017","journal-title":"Sci Rep"},{"key":"2025073014552562000_8.Suppl_9.e013534.66","unstructured":"AH JK , Pilapitiya D , Tsai CJ , et al . Expanding strain coverage of a group A streptococcus pilus-expressing lactococcus lactis mucosal vaccine. Immunol Cell Biol 2023."},{"key":"2025073014552562000_8.Suppl_9.e013534.67","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.8.5448"},{"key":"2025073014552562000_8.Suppl_9.e013534.68","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.9.5662"},{"key":"2025073014552562000_8.Suppl_9.e013534.69","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/CIRCULATIONAHA.121.057301","article-title":"Prothymosin alpha: a novel contributor to estradiol receptor alpha-mediated Cd8(+) T-cell pathogenic responses and recognition of type 1 collagen in rheumatic heart valve disease","volume":"145","author":"Passos","year":"2022","journal-title":"Circulation"},{"key":"2025073014552562000_8.Suppl_9.e013534.70","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau3776","article-title":"Recurrent group A Streptococcus Tonsillitis is an Immunosusceptibility disease involving antibody deficiency and aberrant TFH cells","volume":"11","author":"Dan","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025073014552562000_8.Suppl_9.e013534.71","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/167089","article-title":"Correlates of protection for M protein-based vaccines against group A streptococcus","volume":"2015","author":"Tsoi","year":"2015","journal-title":"J Immunol Res"},{"key":"2025073014552562000_8.Suppl_9.e013534.72","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fux057"},{"key":"2025073014552562000_8.Suppl_9.e013534.73","doi-asserted-by":"publisher","DOI":"10.1111\/mmi.13556"},{"key":"2025073014552562000_8.Suppl_9.e013534.74","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-022-00593-8","article-title":"Correlates of immunity to group A streptococcus: a pathway to vaccine development","volume":"8","author":"Frost","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2025073014552562000_8.Suppl_9.e013534.75","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/trstmh\/trz014","article-title":"Neglecting the neglected: the objective evidence of underfunding in rheumatic heart disease","volume":"113","author":"Macleod","year":"2019","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2025073014552562000_8.Suppl_9.e013534.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.010"},{"key":"2025073014552562000_8.Suppl_9.e013534.77","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/cid\/ciac291","article-title":"A systematic framework for prioritizing burden of disease data required for vaccine development and implementation: the case for group A streptococcal diseases","volume":"75","author":"Moore","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025073014552562000_8.Suppl_9.e013534.78","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1080\/21645515.2018.1470725","article-title":"Global Rotavirus vaccine introductions and coverage: 2006 - 2016","volume":"14","author":"Abou-Nader","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2025073014552562000_8.Suppl_9.e013534.79","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1016\/j.vaccine.2021.08.101","article-title":"Collaboration in times of crisis: a study on COVID-19 vaccine R&Amp;Amp;Amp;Amp;Amp;D partnerships","volume":"39","author":"Druedahl","year":"2021","journal-title":"Vaccine"},{"key":"2025073014552562000_8.Suppl_9.e013534.80","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1377\/hlthaff.2020.02012","article-title":"How new models of vaccine development for COVID-19 have helped address an epic public health crisis","volume":"40","author":"Bloom","year":"2021","journal-title":"Health Aff (Millwood)"},{"key":"2025073014552562000_8.Suppl_9.e013534.81","unstructured":"IVB master deck. n.d. Available: who.int"},{"key":"2025073014552562000_8.Suppl_9.e013534.82","unstructured":"WHO expert review of group A streptococcus vaccines. 2022."},{"key":"2025073014552562000_8.Suppl_9.e013534.83","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-022-02829-3","article-title":"Global burden of rheumatic heart disease: trends from 1990 to 2019","volume":"24","author":"Ou","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2025073014552562000_8.Suppl_9.e013534.84","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3201\/eid2701.191791","article-title":"Rising ethnic inequalities in acute rheumatic fever and rheumatic heart disease, New Zealand, 2000-2018","volume":"27","author":"Bennett","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2025073014552562000_8.Suppl_9.e013534.85","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016851","article-title":"Contemporary incidence and prevalence of rheumatic fever and rheumatic heart disease in Australia using linked data: the case for policy change","volume":"9","author":"Katzenellenbogen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025073014552562000_8.Suppl_9.e013534.86","doi-asserted-by":"crossref","unstructured":"Jackson J , Sonneveld N , Rashid H , et al . Vaccine preventable diseases and vaccination coverage in aboriginal and Torres Strait Islander people. Commun Dis Intell (2018) 2016;47. doi:10.33321\/cdi.2023.47.32","DOI":"10.33321\/cdi.2023.47.32"},{"key":"2025073014552562000_8.Suppl_9.e013534.87","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00984-3"},{"key":"2025073014552562000_8.Suppl_9.e013534.88","first-page":"92","article-title":"New Zealand\u2019s immunisation policy fails again and entrenches ethnic disparities","volume":"134","author":"Sinclair","year":"2021","journal-title":"The New Zealand Medical Journal (Online)"},{"key":"2025073014552562000_8.Suppl_9.e013534.89","article-title":"Interventions for improving coverage of childhood Immunisation in Low- and middle-income countries","volume":"7","author":"Oyo-Ita","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025073014552562000_8.Suppl_9.e013534.90","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-021-11466-5","article-title":"Factors influencing childhood Immunisation uptake in Africa: a systematic review","volume":"21","author":"Galadima","year":"2021","journal-title":"BMC Public Health"},{"key":"2025073014552562000_8.Suppl_9.e013534.91","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11030563","article-title":"Wiysonge CS: a systematic review of factors that influence parents' views and practices around routine childhood vaccination in Africa: a qualitative evidence synthesis","volume":"11","author":"Mavundza","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"2025073014552562000_8.Suppl_9.e013534.92","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.vaccine.2020.11.043","article-title":"Mobile phone reminders for enhancing uptake, completeness and timeliness of routine childhood immunization in low and middle income countries: a systematic review and meta-analysis","volume":"39","author":"Yunusa","year":"2021","journal-title":"Vaccine"},{"key":"2025073014552562000_8.Suppl_9.e013534.93","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.09.005"},{"key":"2025073014552562000_8.Suppl_9.e013534.94","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s13317-013-0053-8","article-title":"Streptincor: a model of anti-streptococcus pyogenes vaccine reviewed","volume":"4","author":"Guilherme","year":"2013","journal-title":"Auto Immun Highlights"},{"key":"2025073014552562000_8.Suppl_9.e013534.95","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-46244-2","article-title":"Group A streptococcus adsorbed vaccine: repeated intramuscular dose toxicity test in minipigs","volume":"9","author":"Postol","year":"2019","journal-title":"Sci Rep"},{"key":"2025073014552562000_8.Suppl_9.e013534.96","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14157-7","article-title":"Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards phase I trial","volume":"7","author":"Pandey","year":"2017","journal-title":"Sci Rep"},{"key":"2025073014552562000_8.Suppl_9.e013534.97","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700836"},{"key":"2025073014552562000_8.Suppl_9.e013534.98","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1574224"},{"key":"2025073014552562000_8.Suppl_9.e013534.99","doi-asserted-by":"crossref","unstructured":"Feikin DR , Flannery B , Hamel MJ , et al . Vaccines for children in Low- and middle-income countries. In: Black RE , Laxminarayan R , Temmerman M , et al , eds. Reproductive, Maternal, Newborn, and Child Health: Disease Control Priorities Third Edition (Volume 2). edn. 2016: doi:10.1596\/978-1-4648-0348-2","DOI":"10.1596\/978-1-4648-0348-2_ch10"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2023-013534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T21:55:39Z","timestamp":1753912539000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2023-013534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":99,"journal-issue":{"issue":"Suppl 9","published-online":{"date-parts":[[2023,12,12]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/bmjgh-2023-013534"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2023-013534","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}